[PDF] Top 20 APP processing in Alzheimer's disease
Has 10000 "APP processing in Alzheimer's disease" found on our website. Below are the top 20 most common "APP processing in Alzheimer's disease".
APP processing in Alzheimer's disease
... cleave APP at position Asp664 (based on the APP695 sequence) within the cytoplasmic tail during apoptosis to release a fragment containing the last 31 amino acids of APP (called ...amyloidogenic ... See full document
13
ALZHEIMER’S DISEASE: A REVIEW
... Almost all early-onset cases of AD can be attributed to alterations on chromosomes 1, 14, or 21. The majority and most aggressive early-onset cases are attributed to mutations of an Alzheimer’s gene located on chromosome ... See full document
9
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
... The APP selectivity of the sulfonamide core appears to be very sensitive to structural ...’ s [91,92], as well as 4-cyclohexyl sulfones [12,93] have been reported as equipotent on APP and ...of ... See full document
21
Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice
... an S-enantiomer, whereas citalopram used in the other studies is a racemic mixture of both S- and R-enantiomers in the ratio of ...the S-enantiomer [42], leaving escitalopram more potent than ... See full document
12
Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set
... For neuropsychological tests, baseline volume of WMH had the strongest effects for accelerated decline on measures that assess cognitive flexibility (TMT-B), working memory and information processing speed (WAIS-R ... See full document
13
Alzheimer’s Disease Assessment Scale–Cognitive subscale variants in mild cognitive impairment and mild Alzheimer’s disease: change over time and the effect of enrichment strategies
... Byrd Alzheimer ’ s Institute; New York University; Duke University Medical Center; University of Pennsylvania; University of Kentucky; University of Pittsburgh; University of Rochester Medical Center; ... See full document
13
Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort
... Background: The natural history and disease mechanisms of Alzheimer ’ s disease and related disorders (ADRD) are still poorly understood. Very few resources are available to scrutinise ... See full document
13
Adult hippocampal neurogenesis and its role in Alzheimer's disease
... Alzheimer’s disease (AD), first described by the German neuropathologist Alois Alzheimer as Dementia Praecox in 1907, is an age-related neurodegenerative disease characterized by progressive loss of ... See full document
9
Segregation of a rare TTC3 variant in an extended family with late-onset Alzheimer disease
... DISCUSSION We performed WES in an extended, multigenerational family with an autosomal domi- nant inheritance pattern of LOAD. Disease segrega- tion analyses identified the TTC3 p.S1038C substitution as the only ... See full document
9
Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
... Alzheimer’s disease demen- tia (AD-D) comprising patients with probable AD dementia with high evidence of AD pathophysiological process, patients with possible AD dementia with high evidence of AD ... See full document
8
Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE)
... Memory services are often approached by individuals who subjectively experience decline in cognitive func- tioning but perform within the age, sex, and education- adjusted normal limits on standard cognitive tests. In- ... See full document
10
For debate: substituting placebo controls in long-term Alzheimer's prevention trials
... AD disease trajectories from its presymptomatic to sympto- matic ...modeled disease course; that is, with their predicted endpoints and trajectories had they not been ... See full document
11
Three-dimensional analysis of synapses in the transentorhinal cortex of Alzheimer’s disease patients
... Analysis of neuropil in the stacks of images of layer II of the TEC revealed that AD patients did not show a sig- nificantly lower synaptic density. However, since we found that TEC thickness in AD patients was 35% thin- ... See full document
15
Decreased cortical FADD protein is associated with clinical dementia and cognitive decline in an elderly community sample
... Protein expression levels of FADD species did not differ in the DLPFC of MAP participants displaying cerebrovascular diseases (including infarcts), Lewy bod- ies, cortical atrophy, or hippocampal sclerosis from those who ... See full document
14
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
... for disease intervention in AD, as Aβ immunotherapy in general confers a lower risk of side effects in a vulner- able patient population during long-term treatment as compared with small-molecule anti-Aβ ... See full document
8
Cognitive reserve and clinical progression in Alzheimer diseaseA paradoxical relationship
... In the present study we investigated how CR, defined as the degree to which an individual’s observed cerebral damage was higher or lower than predicted from cognitive performance, affected clinical progression in AD. In an ... See full document
14
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
... of APP heteromers in CSF, comprising both sAPPα/sAPPβ and also soluble full-length APP, and we have shown that these heteromers affect the determination of sAPP by ELISA ... See full document
9
PKR involvement in Alzheimer’s disease
... In vitro studies have revealed that PKR is activated by Aβ peptide toxicity. In 2002, a report showed that, in a human neuroblastoma cell line and in primary neuronal cultures, Aβ exposure induced PKR activation, eIF2α ... See full document
10
Cross-talk of membrane lipids and Alzheimer-related proteins
... ’ s disease (AD) is neuropathologically characterized by the combined occurrence of extracellular β - amyloid plaques and intracellular neurofibrillary tangles in the ... See full document
12
Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort
... Pooled-DNA sequencing was performed as previously described [7,13]. The concentration of genomic DNA was quantified by Quant-iT™ PicoGreen (Invitrogen Corpora- tion, Carlsbad, CA, USA) reagent, and normalized amounts of ... See full document
9
Related subjects